Pharmicell Co.,Ltd. Q3 operating profit KRW 11.9 billion, up 46.6% from a year earlier
PAI summary · Not investment advice
PharmiCell sold KRW 37.0 billion in Q3 and earned KRW 11.9 billion from its main business, up 46.6% from a year earlier and down 9.8% from the prior quarter.
Operating profit · 3 months
KRW 11.9 billion
Key facts
- Revenue (3 months)
- KRW 37.0 billion
- Net income (3 months)
- KRW 8.3 billion
- Period
- Q3 (cumulative 2026.01.01 ~ 2026.09.30)
- Revenue (prior-year 3 months)
- KRW 25.6 billion
- Revenue (year to date)
- KRW 112.6 billion
- Operating profit (prior-year 3 months)
- KRW 8.1 billion
- Operating profit (year to date)
- KRW 38.2 billion
- Net income (prior-year 3 months)
- KRW 8.8 billion
- Net income (year to date)
- KRW 30.4 billion
Commentary
AI commentary · Not investment advice
What happened
Pharmicell filed its quarterly report with separate (non-consolidated) results for the 3rd quarter of 2026. Sales for the 3 months were KRW 36.97 billion, up 44.1% from the same 3 months a year earlier (KRW 25.65 billion). They fell 5.2% from the previous quarter.
In the company's terms
Operating profit (money earned from the core business) for the 3 months was KRW 11.93 billion. That is up 46.6% from a year earlier (KRW 8.14 billion) and down 9.8% from the previous quarter. Net income (the final profit left after all costs and taxes) was KRW 8.29 billion. That is down 5.6% from a year earlier (KRW 8.78 billion) and down 20.1% from the previous quarter.
What changes for shareholders
For the year to date (Jan 1 to Sep 30), sales were KRW 112.64 billion. Operating profit was KRW 38.24 billion, and net income was KRW 30.37 billion.
Show Korean comments
Comments
No comments yet
Comments from shareholders will appear here.
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist